Ann: Sygenus shows longer lasting effect on pain than morphine, page-9

Not only these preliminary results are outstanding, but RGS secretions technology also means MSCs secretions can be used and administered in multiple ways: cream, lotions, injection.

In terms of marketability this is great news: partnerships, licensing, etc. with large players opening the way to income (royalties), JVs and therefore financial success much quicker than with other cell therapies.

Any SP below 0.25 is a bargain right now. Below 0.50 a good buy. Around 0.75, probably close to market value IMO.